

Markus Lundgren

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/667252/publications.pdf>

Version: 2024-02-01

43
papers

844
citations

706676

14
h-index

591227

27
g-index

43
all docs

43
docs citations

43
times ranked

1045
citing authors

#	ARTICLE	IF	CITATIONS
1	Progression of type 1 diabetes from latency to symptomatic disease is predicted by distinct autoimmune trajectories. <i>Nature Communications</i> , 2022, 13, 1514.	5.8	16
2	Multiplex agglutination-PCR (ADAP) autoantibody assays compared to radiobinding autoantibodies in type 1 diabetes and celiac disease. <i>Journal of Immunological Methods</i> , 2022, 506, 113265.	0.6	9
3	Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies. <i>Journal of Immunology Research</i> , 2022, 2022, 1-17.	0.9	1
4	Two-age islet-autoantibody screening for childhood type 1 diabetes: a prospective cohort study. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 589-596.	5.5	16
5	DPVis: Visual Analytics With Hidden Markov Models for Disease Progression Pathways. <i>IEEE Transactions on Visualization and Computer Graphics</i> , 2021, 27, 3685-3700.	2.9	35
6	Beta cell function in participants with single or multiple islet autoantibodies at baseline in the TEDDY Family Prevention Study: TEFA. <i>Endocrinology, Diabetes and Metabolism</i> , 2021, 4, e00198.	1.0	3
7	An Age-Related Exponential Decline in the Risk of Multiple Islet Autoantibody Seroconversion During Childhood. <i>Diabetes Care</i> , 2021, 44, 2260-2268.	4.3	23
8	Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count. <i>Endocrine Reviews</i> , 2021, 42, 584-604.	8.9	31
9	Islet Autoimmunity and HLA Markers of Presymptomatic and Clinical Type 1 Diabetes: Joint Analyses of Prospective Cohort Studies in Finland, Germany, Sweden, and the U.S.. <i>Diabetes Care</i> , 2021, 44, 2269-2276.	4.3	27
10	Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts. <i>Diabetes Care</i> , 2021, 44, 2329-2336.	4.3	5
11	First-appearing islet autoantibodies for type 1 diabetes in young children: maternal life events during pregnancy and the child's genetic risk. <i>Diabetologia</i> , 2021, 64, 591-602.	2.9	7
12	Factors Associated With the Decline of C-Peptide in a Cohort of Young Children Diagnosed With Type 1 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e1380-e1388.	1.8	7
13	Supplementation with <i>Bifidobacterium longum</i> subspecies <i>infantis</i> EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol. <i>BMJ Open</i> , 2021, 11, e052449.	0.8	15
14	Heterogeneity of beta-cell function in subjects with multiple islet autoantibodies in the TEDDY family prevention study - TEFA. <i>Clinical Diabetes and Endocrinology</i> , 2021, 7, 23.	1.3	1
15	Imputing Longitudinal Growth Data in International Pediatric Studies: Does CDC Reference Suffice?. <i>AMIA ... Annual Symposium proceedings</i> , 2021, 2021, 754-762.	0.2	1
16	First European Case of Simultaneous Liver and Pancreas Transplantation as Treatment of Wolcott-Rallison Syndrome in a Small Child. <i>Transplantation</i> , 2020, 104, 522-525.	0.5	3
17	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. <i>Diabetes Care</i> , 2020, 43, 5-12.	4.3	220
18	Decreased HLA-DQ expression on peripheral blood cells in children with varying number of beta cell autoantibodies. <i>Journal of Translational Autoimmunity</i> , 2020, 3, 100052.	2.0	5

#	ARTICLE	IF	CITATIONS
19	Hierarchical Order of Distinct Autoantibody Spreading and Progression to Type 1 Diabetes in the TEDDY Study. <i>Diabetes Care</i> , 2020, 43, 2066-2073.	4.3	41
20	Parental anxiety after 5 years of participation in a longitudinal study of children at high risk of type 1 diabetes. <i>Pediatric Diabetes</i> , 2020, 21, 878-889.	1.2	5
21	248-OR: Visualizing Heterogeneous Islet Autoantibody Trajectories of Children Who Develop T1D from Multisite Birth Cohort Studies. <i>Diabetes</i> , 2020, 69, 248-OR.	0.3	0
22	348-OR: Metabolic Phenotype of Autoantibody Positive (AbPos) Long-Term Nonprogressors (LTNPs) to Type 1 Diabetes (T1D). <i>Diabetes</i> , 2020, 69, .	0.3	0
23	342-OR: Optimal Ages for Screening for T1D Risk in Children. <i>Diabetes</i> , 2020, 69, .	0.3	5
24	Modeling Disease Progression Trajectories from Longitudinal Observational Data. <i>AMIA ... Annual Symposium proceedings</i> , 2020, 2020, 668-676.	0.2	3
25	Predicting Type 1 Diabetes Onset using Novel Survival Analysis with Biomarker Ontology. <i>AMIA ... Annual Symposium proceedings</i> , 2020, 2020, 727-736.	0.2	0
26	Effect of screening for type 1 diabetes on early metabolic control: the DiPiS study. <i>Diabetologia</i> , 2019, 62, 53-57.	2.9	16
27	Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. <i>BMJ Open</i> , 2019, 9, e028578.	0.8	62
28	Practical management in Wolcott-Rallison syndrome with associated hypothyroidism, neutropenia, and recurrent liver failure: A case report. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 1133-1138.	0.2	6
29	Predicting Islet Cell Autoimmunity and Type 1 Diabetes: An 8-Year TEDDY Study Progress Report. <i>Diabetes Care</i> , 2019, 42, 1051-1060.	4.3	75
30	1345-P: Presymptomatic and Clinical T1D in The U.S., Sweden, and Finland: Joint Analysis of Four Birth Cohort Studies. <i>Diabetes</i> , 2019, 68, .	0.3	0
31	163-OR: Sensitivity Analysis of Alternate Definitions of Multiple Islet Autoantibody Positivity. <i>Diabetes</i> , 2019, 68, .	0.3	0
32	1690-P: Predicting Onset of Type 1 Diabetes Using a Novel Interaction Model. <i>Diabetes</i> , 2019, 68, .	0.3	0
33	211-OR: Analysis of Longitudinal Autoantibody Profiles and the Progression Rates to Type 1 Diabetes. <i>Diabetes</i> , 2019, 68, .	0.3	0
34	1671-P: Comorbid Autoimmune Disease in Participants at Risk for Type 1 Diabetes. <i>Diabetes</i> , 2019, 68, .	0.3	0
35	First trimester enterovirus IgM and beta cell autoantibodies in mothers to children affected by type 1 diabetes autoimmunity before 7 years of age. <i>Journal of Reproductive Immunology</i> , 2018, 127, 1-6.	0.8	4
36	Plasma 25-Hydroxyvitamin D Concentration and Risk of Islet Autoimmunity. <i>Diabetes</i> , 2018, 67, 146-154.	0.3	72

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial. <i>Pediatric Diabetes</i> , 2018, 19, 410-419.	1.2	45
38	Childhood thyroid autoimmunity and relation to islet autoantibodies in children at risk for type 1 diabetes in the diabetes prediction in skÅ¥ne (DiPiS) study. <i>Autoimmunity</i> , 2018, 51, 228-237.	1.2	18
39	Influence of early-life parental severe life events on the risk of type 1 diabetes in children: the DiPiS study. <i>Acta Diabetologica</i> , 2018, 55, 797-804.	1.2	9
40	Are Perinatal Events Risk Factors for Childhood Thyroid Autoimmunity?. <i>European Thyroid Journal</i> , 2017, 6, 298-306.	1.2	5
41	Analgesic antipyretic use among young children in the TEDDY study: no association with islet autoimmunity. <i>BMC Pediatrics</i> , 2017, 17, 127.	0.7	17
42	Cord blood insulinoma-associated protein 2 autoantibodies are associated with increased risk of type 1 diabetes in the population-based Diabetes Prediction in SkÅ¥ne study. <i>Diabetologia</i> , 2015, 58, 75-78.	2.9	10
43	Reduced morbidity at diagnosis and improved glycemic control in children previously enrolled in DiPiS follow-up. <i>Pediatric Diabetes</i> , 2014, 15, 494-501.	1.2	26